Orbis Medicines
Orbis Medicines is focused on the development of next-generation oral macrocycle drugs, utilizing its proprietary nGen platform. The platform leverages automated chemistry and machine learning to systematically design oral macrocycles, initially targeting validated blockbuster biologic targets.
Leadership & Board
- Current Number of Employees
- 45
- Current LinkedIn Followers
- 6,653
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $90M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $90M
- Latest Funding Round
- Series A
- Post-Money Valuation
- ―
Company Momentum Positive
Orbis Medicines LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Employee Trend
Orbis Medicines had 45 employees as of October 12, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Orbis Medicines had 6,653 followers as of October 12, 2026. The number of followers increased by 105 (1.60%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Aug 14, 2025 | Series A | $90.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Eli Lilly and Company | Series A |
| Forbion | Series A |
| Novo Holdings | Series A |
| Export and Investment Fund of Denmark | Series A |
| New Enterprise Associates | Series A |
| Cormorant | Series A |
Similar Companies
A snapshot of private companies similar to Orbis Medicines, helping you discover and navigate related company profiles.
Related News and Analysis
